A phase III trial of the drug Enzalutamide extended the life of advanced prostate cancer patients by an average of five months, U.S. researchers found. Study co-author Dr. Thomas Flaig, medical director of the University of Colorado Cancer Center's Clinical Investigations Shared Resource and the...
FULL ARTICLE AT United Press International